Herantis Pharma PLC · OMXHEX:HRTIS

Herantis Pharma — TreatER Webcast (November 2020)

13 slides from Herantis Pharma's conference presentation, Nov 18, 2020

  1. Slide 1: CDNF in the First-in-Human Clinical Trial

    CDNF in the First-in-Human Clinical Trial 12 months clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s Magnus Sjögren, Chief Medical Officer at Herantis Pharma Plc. And Professor Per Svenningsson, Principal Investigator, Karoli

  2. Slide 2: The Clinical Trial

    The Clinical Trial The primary endpoint of this First-in-Human study was safety and tolerability Ø secondary endpoints included evaluation of efficacy of CDNF 17 patients with Parkinson’s disease The clinical trial was conducted at 3 clinical sites and 2 PET centers in Finland and Sweden – Karolinsk

  3. Slide 3: The Clinical Trial Design and Characteristics

    The Clinical Trial Design and Characteristics Main Study – 6 months Extension Study – 6 months Follow-up Study – 4 years Treatment groups Mid-dose CDNF Vehicle (n=6) High-dose CDNF Safety follow-up Mid-dose CDNF (n=6) All patients High-dose CDNF (n=5) Safety Follow-up, Monthly Infusions x 6 Monthly

  4. Slide 4: Clinical Trial Procedures

    Clinical Trial Procedures Altogether 26 Visits Over A Period Of 16 Months v 12 treatment infusions, once every month Many Scans Taken For Surgical Planning And Safety Neurosurgical Implantation Of The Drug Delivery Device Several Off-medication Session With Stay Overnight, Travel to PET-Centre, Diar

  5. Slide 5: Renishaw's Drug Delivery System

    Renishaw’s Drug Delivery System © 2014-2020 HERANTIS PHARMA Plc. All rights reserved. 5

  6. Slide 6: CDNF in the First-in-Human clinical trial 12 Months Primary Endpoint - Safety

    CDNF in the First-in-Human clinical trial 12 Months Primary Endpoint - Safety

  7. Slide 7: Safety Assessment During the Clinical Trial

    Safety Assessment During the Clinical Trial Safety Was Assessed At Any Time During The Study: • By asking the patient if they have experienced any new adverse events since the previous visit, also events unrelated to the study treatment Laboratory Blood And Urine Testing At Every Visit • Also testin

  8. Slide 8: Observed Adverse Events Profile

    Observed Adverse Events* Profile NERVOUS SYSTEM DISORDERS GENERAL DISORDERS AND ADMINISTRATION SITE 9% CONDITIONS PSYCHIATRIC DISORDERS 10 % 29 % INJURY, POISONING AND PROCEDURAL COMPLICATIONS 5% INFECTIONS AND INFESTATIONS GASTROINTESTINAL DISORDERS 6% MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER

  9. Slide 9: The Most Common Reported Drug-Related Adverse Events

    The Most Common Reported Drug-Related Adverse Events Altogether 68 Drug-related Adverse Events Were Reported During the 12-Month Treatment Period Were Mild to Moderate, and Majority Has Recovered: Central Nervous General Other Disorders System Disorders Disorders Dyskinesias, Headache, Feeling cold,

  10. Slide 10: Serious Adverse (Device) Events

    Serious Adverse (Device) Events Altogether 9 serious adverse (device) events were reported in the Main and Extension study: • 1 serious event occured prior to surgery or treatment start – purulent sinusitis • 5 serious adverse events occuring after surgery, prior to treatment start: ○ Confusion (2x)

  11. Slide 11: All Recovered from Serious Adverse (Device) Events

    All Recovered from Serious Adverse (Device) Events • Brain abscess occured in Main study during the first 6-month period Infectious events: • Port skin necrosis in Main study during the first 6-month period Risk mitigation improvements made to surgical procedure, infusion procedure, device maintenan

  12. Slide 12: Summary of 12-Month Safety Data

    Summary of 12-Month Safety Data 12 Monthly Intracerebral Doses of CDNF was Safe and Well-Tolerated Majority of the Reported Drug-related Adverse Events Were Mild And all Patients have Recovered Similar Safety Profile in Main and Extension Study, Less Reported Adverse Events in Extension ○ No clear d

  13. Slide 13: Thank you!

    Thank you! 24 11/20/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.

Herantis Pharma — TreatER Webcast (November 2020) on 6ix